Everyone knows real-world evidence (RWE) has value. But due to technology challenges, biopharma companies are struggling to achieve the full benefit of their RWE programs. Databricks recently surveyed 109 executives to get a better idea of what’s working, what’s not and the path forward.
Get the full results in this whitepaper. You’ll find out: